JP2019501191A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501191A5 JP2019501191A5 JP2018535283A JP2018535283A JP2019501191A5 JP 2019501191 A5 JP2019501191 A5 JP 2019501191A5 JP 2018535283 A JP2018535283 A JP 2018535283A JP 2018535283 A JP2018535283 A JP 2018535283A JP 2019501191 A5 JP2019501191 A5 JP 2019501191A5
- Authority
- JP
- Japan
- Prior art keywords
- lyophilized formulation
- present
- amount
- total weight
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021068923A JP7201732B2 (ja) | 2016-01-08 | 2021-04-15 | ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドの製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662276756P | 2016-01-08 | 2016-01-08 | |
| US62/276,756 | 2016-01-08 | ||
| PCT/US2017/012483 WO2017120437A1 (en) | 2016-01-08 | 2017-01-06 | Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021068923A Division JP7201732B2 (ja) | 2016-01-08 | 2021-04-15 | ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドの製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501191A JP2019501191A (ja) | 2019-01-17 |
| JP2019501191A5 true JP2019501191A5 (enExample) | 2020-06-25 |
| JP6871256B2 JP6871256B2 (ja) | 2021-05-12 |
Family
ID=59273934
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018535283A Active JP6871256B2 (ja) | 2016-01-08 | 2017-01-06 | ２−（４−クロロフェニル）−ｎ−（（２−（２，６−ジオキソピペリジン−３−イル）−１−オキソイソインドリン−５−イル）メチル）−２，２−ジフルオロアセトアミドの製剤 |
| JP2021068923A Active JP7201732B2 (ja) | 2016-01-08 | 2021-04-15 | ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドの製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021068923A Active JP7201732B2 (ja) | 2016-01-08 | 2021-04-15 | ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドの製剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US10052315B2 (enExample) |
| EP (2) | EP4275707A3 (enExample) |
| JP (2) | JP6871256B2 (enExample) |
| KR (1) | KR20180100565A (enExample) |
| CN (2) | CN113633634A (enExample) |
| AU (2) | AU2017205167B2 (enExample) |
| BR (1) | BR112018013884A2 (enExample) |
| CA (1) | CA3010797C (enExample) |
| CL (1) | CL2018001830A1 (enExample) |
| CO (1) | CO2018008305A2 (enExample) |
| EA (1) | EA037508B1 (enExample) |
| EC (1) | ECSP18051143A (enExample) |
| ES (1) | ES2956767T3 (enExample) |
| IL (1) | IL260403B (enExample) |
| MX (1) | MX382150B (enExample) |
| SA (1) | SA518391983B1 (enExample) |
| SG (2) | SG10202007913WA (enExample) |
| WO (1) | WO2017120437A1 (enExample) |
| ZA (1) | ZA201804482B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9499514B2 (en) | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| US10052315B2 (en) * | 2016-01-08 | 2018-08-21 | Celgene Corporation | Formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| EP3399980B1 (en) | 2016-01-08 | 2025-07-16 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
| SG11201809501PA (en) | 2016-06-06 | 2018-12-28 | Celgene Corp | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| EP4201399A3 (en) * | 2017-06-30 | 2023-08-09 | Celgene Corporation | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide |
| EA202191833A1 (ru) * | 2018-12-31 | 2021-10-11 | Селджин Корпорейшн | Композиции и способы применения 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида |
| CA3157196A1 (en) * | 2019-11-05 | 2021-05-14 | Celgene Corporation | Combination therapy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide |
| IL293481A (en) | 2019-12-06 | 2022-08-01 | Celgene Corp | Processes for the preparation of 2-(4-chlorophenyl)-n-((2-(2,6-dioxypyridin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| CN117242060B (zh) | 2021-01-13 | 2026-07-17 | 蒙特罗莎治疗股份有限公司 | 异吲哚啉酮化合物 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| EP1456652A4 (en) | 2001-11-13 | 2005-11-02 | Dana Farber Cancer Inst Inc | IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR |
| US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| CN100457098C (zh) * | 2006-12-20 | 2009-02-04 | 南京科源医药技术有限公司 | 甲磺酸萘莫司他冻干粉针剂及其制备方法 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| CN101224296A (zh) * | 2008-02-01 | 2008-07-23 | 山东先声麦得津生物制药有限公司 | 一种稳定的重组人血管内皮抑制素制剂及其制备工艺 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| CA2957226C (en) * | 2008-10-29 | 2018-08-14 | Celgene Corporation | Isoindoline compounds for use in the treatment of cancer |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| EP2699091B1 (en) * | 2011-03-28 | 2017-06-21 | DeuteRx, LLC | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| US8974811B2 (en) * | 2013-03-14 | 2015-03-10 | Hikma Pharmaceuticals | Stabilized pharmaceutical formulations comprising antineoplastic compounds |
| WO2014179661A1 (en) | 2013-05-03 | 2014-11-06 | Celgene Corporation | Methods for treating cancer using combination therapy |
| US9499514B2 (en) | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| US10052315B2 (en) * | 2016-01-08 | 2018-08-21 | Celgene Corporation | Formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| TWI782395B (zh) | 2016-01-08 | 2022-11-01 | 美商西建公司 | 抗增生化合物，及其醫藥組合物及用途 |
| CA3010794A1 (en) | 2016-01-08 | 2017-07-13 | Celgene Corporation | Solid forms of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses |
| JP2019011495A (ja) | 2017-06-30 | 2019-01-24 | 株式会社Ｕａｃｊ押出加工 | 熱交換器に配管部材を接続するためのアルミニウム合金製コネクタ及び該コネクタを備える熱交換器接続用配管部材、並びにこれらの製造方法 |
| EA202191833A1 (ru) | 2018-12-31 | 2021-10-11 | Селджин Корпорейшн | Композиции и способы применения 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида |
| CA3157196A1 (en) | 2019-11-05 | 2021-05-14 | Celgene Corporation | Combination therapy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide |
-
2017
- 2017-01-06 US US15/400,791 patent/US10052315B2/en active Active
- 2017-01-06 WO PCT/US2017/012483 patent/WO2017120437A1/en not_active Ceased
- 2017-01-06 ES ES17736406T patent/ES2956767T3/es active Active
- 2017-01-06 BR BR112018013884A patent/BR112018013884A2/pt not_active Application Discontinuation
- 2017-01-06 EA EA201891578A patent/EA037508B1/ru unknown
- 2017-01-06 SG SG10202007913WA patent/SG10202007913WA/en unknown
- 2017-01-06 MX MX2018008429A patent/MX382150B/es unknown
- 2017-01-06 CN CN202110818391.8A patent/CN113633634A/zh active Pending
- 2017-01-06 JP JP2018535283A patent/JP6871256B2/ja active Active
- 2017-01-06 KR KR1020187019190A patent/KR20180100565A/ko not_active Ceased
- 2017-01-06 EP EP23181094.6A patent/EP4275707A3/en not_active Withdrawn
- 2017-01-06 AU AU2017205167A patent/AU2017205167B2/en active Active
- 2017-01-06 EP EP17736406.4A patent/EP3399979B9/en active Active
- 2017-01-06 CN CN201780005873.3A patent/CN108601777B/zh active Active
- 2017-01-06 SG SG11201805777QA patent/SG11201805777QA/en unknown
- 2017-01-06 CA CA3010797A patent/CA3010797C/en active Active
-
2018
- 2018-07-03 IL IL260403A patent/IL260403B/en unknown
- 2018-07-04 CL CL2018001830A patent/CL2018001830A1/es unknown
- 2018-07-04 ZA ZA201804482A patent/ZA201804482B/en unknown
- 2018-07-05 SA SA518391983A patent/SA518391983B1/ar unknown
- 2018-07-06 EC ECSENADI201851143A patent/ECSP18051143A/es unknown
- 2018-07-19 US US16/040,450 patent/US10449187B2/en active Active
- 2018-08-08 CO CONC2018/0008305A patent/CO2018008305A2/es unknown
-
2019
- 2019-09-09 US US16/565,346 patent/US11129821B2/en active Active
-
2021
- 2021-04-15 JP JP2021068923A patent/JP7201732B2/ja active Active
- 2021-08-25 US US17/412,187 patent/US11883389B2/en active Active
- 2021-09-29 AU AU2021240184A patent/AU2021240184A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021113206A5 (enExample) | ||
| HRP20230210T1 (hr) | Pripravci i postupci upotrebe 2-(4-klorofenil)-n-((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-5-il)metil)-2,2-difluoroacetamida | |
| JP2019131596A5 (enExample) | ||
| ES2424476T3 (es) | Nanopartículas cargadas con fármaco antitumoral quimioterápico | |
| JP7229999B2 (ja) | ダプトマイシン製剤 | |
| JP2019517587A5 (enExample) | ||
| JP6734971B2 (ja) | がん治療薬 | |
| JP2009530413A5 (enExample) | ||
| EP1613356A1 (en) | A fluoroquinolone aqueous formulation of a ph between 4 and 7 comprising i.a. cyclodextrin, hydroxy acid | |
| JP2013511557A5 (enExample) | ||
| JP2013532729A5 (enExample) | ||
| JP7597778B2 (ja) | シクロデキストリン及びブスルファンを含有する組成物 | |
| JP2025143385A (ja) | クロファジミンの組成物、それを含む組合せ、その調製プロセス、それを含む使用及び処置方法 | |
| JP2021528368A5 (enExample) | ||
| FR3056108B1 (fr) | Utilisation des harringtonines dans le traitement cancer du sein, notamment triple-negatif | |
| AU2003227702A1 (en) | Epothilone derivative for the treatment of hepatoma and other cancer diseases | |
| JP2019516765A5 (enExample) | ||
| CN113329734A (zh) | 新颖的药物制剂 | |
| JP2016508138A (ja) | カバジタキセル組成物 | |
| JP7149991B2 (ja) | 発泡剤を含む抗微生物組成物 | |
| WO2019242688A1 (zh) | 3-羟基氨基苯甲酸与索拉非尼联合用药治疗肿瘤 | |
| JP2025510725A5 (enExample) | ||
| WO2014131360A1 (zh) | 普罗布考及其衍生物抗肿瘤转移的用途 | |
| JP2020536126A (ja) | 経口ベンダムスチン製剤 | |
| WO2004030673A1 (ja) | 経口吸収性が改善された抗菌性医薬組成物 |